Case of immune-mediated necrotizing myopathy associated with anti-signal recognition particle antibodies: Dramatic improvement after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for intravascular large B-cell lymphoma

2018 ◽  
Vol 9 (3) ◽  
pp. 177-181 ◽  
Author(s):  
Hiroyasu Komiya ◽  
Maki Hagihara ◽  
Kenichi Tanaka ◽  
Mikiko Tada ◽  
Hideto Joki ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
Signal Recognition Particle ◽  
B Cell Lymphoma ◽  
Dramatic Improvement ◽  
Signal Recognition ◽  
Necrotizing Myopathy ◽  
Large B Cell Lymphoma ◽  
Immune Mediated ◽  
Large B Cell

Nonregenerative immune-mediated anemia associated with a diffuse large B-cell lymphoma in a captive jaguar (Panthera onca )

2017 ◽  
Vol 46 (4) ◽  
pp. 597-604 ◽  
Author(s):  
Monika A. Keresztes ◽  
Manfred Henrich ◽  
Penelope Baloi ◽  
Sascha Gerst ◽  
Jens-Christian Rudnick ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Panthera Onca ◽  
Large B Cell Lymphoma ◽  
Immune Mediated ◽  
Large B Cell

scholarly journals Lactic acidosis: a unique presentation of diffuse large B-cell lymphoma

2019 ◽  
Vol 12 (10) ◽  
pp. e230277 ◽  
Author(s):  
Turab Jawaid Mohammed ◽  
Rohit Gosain ◽  
Rajeev Sharma ◽  
Pallawi Torka
Keyword(s):  
Lactic Acidosis ◽  
B Cell ◽  
Cell Lymphoma ◽  
Performance Status ◽  
B Cell Lymphoma ◽  
Intrathecal Methotrexate ◽  
Dramatic Improvement ◽  
Metabolic Encephalopathy ◽  
Large B Cell Lymphoma ◽  
Large B Cell

An elderly man in the seventh decade of life was brought to the hospital with worsening mental status. Blood tests revealed anaemia and thrombocytopenia with elevated lactate dehydrogenase and serum lactate levels. CT scan showed bulky thoracic and abdominal lymphadenopathy with splenomegaly. A positron emission tomography scan confirmed the above and in addition, revealed bilateral adrenal involvement. Bone marrow biopsy revealed non-germinal centre B-cell-like (non-GCB)-diffuse large B-cell lymphoma (DLBCL). Prompt treatment with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab with intrathecal methotrexate chemotherapy resulted in a dramatic improvement in the patient’s condition. This vignette serves as a reminder to include aggressive lymphomas like DLBCL in the differential diagnoses of patients presenting with metabolic encephalopathy and lactic acidosis. Our patient was moribund at presentation with poor sensorium and failure to thrive. The dilemma was whether to take an aggressive stand and start chemotherapy urgently or whether to stabilise the patient first and then consider the treatment of DLBCL. We make a case for initiating therapy promptly in such patients irrespective of their performance status.

scholarly journals Prognostic Impact of Immunohistochemical and Molecular Features of Diffuse Large B-cell Lymphoma

2019 ◽  
Vol 2 (17) ◽  
pp. 5-7
Author(s):  
E. V. Kharchenko ◽  
A. S. Artemyeva ◽  
I. L. Polyatskin ◽  
T. Yu. Semiglazova
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Response To Therapy ◽  
Dramatic Improvement ◽  
Prognostic Impact ◽  
Treatment Intensification ◽  
Molecular Features ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Diffuse large B-cell lymphoma is the most common type of non-Hodgkin’s lymphoma. Despite of dramatic improvement during last decades in rituximab-era, 30 % of patients are still resistant to initial therapy. Molecular genetics made significant contribution in our understanding of pathogenesis of disease, genetic and epigenetic disorders which have direct impact on cell’s growth, differentiation and immune response. This allowed distinguishing more aggressive subtypes of diffuse large B-cell lymphoma, which can potentially benefit from early-treatment intensification. In this review, we will discuss immunohistochemical and molecular features of diffuse large B-cell lymphoma and its impact on course, prognosis and response to therapy.

scholarly journals Immune-mediated Neuropathy with Anti-disialosyl IgM Antibodies in Diffuse Large B-cell Lymphoma: A Case Report and Literature Review

2015 ◽  
Vol 54 (13) ◽  
pp. 1647-1651 ◽  
Author(s):  
Gen Shihashi ◽  
Takuya Yagi ◽  
Shigeaki Suzuki ◽  
Morinobu Seki ◽  
Sumiko Kohashi ◽  
...  
Keyword(s):  
Case Report ◽  
Literature Review ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Igm Antibodies ◽  
Large B Cell Lymphoma ◽  
Immune Mediated ◽  
Large B Cell

scholarly journals LyRIC indeterminate response and Immune‐mediated pseudoprogression of diffuse large B‐cell lymphoma following polatuzumab‐based salvage therapy

2020 ◽  
Vol 189 (6) ◽  
Author(s):  
Alexander T. J. Lee ◽  
Ayoma D. Attygale ◽  
Rajaei K. Sharma ◽  
Sunil Iyengar ◽  
Dima El‐Sharkawi ◽  
...  
Keyword(s):  
B Cell ◽  
Salvage Therapy ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Immune Mediated ◽  
Large B Cell

Lymphome

Praxis ◽  
2016 ◽  
Vol 105 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Andreas Lohri
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Staging System ◽  
Maligne Lymphome ◽  
Interim Pet ◽  
Large B Cell Lymphoma ◽  
Ann Arbor ◽  
Large B Cell

Zusammenfassung. Maligne Lymphome unterteilen sich zwar in über 60 Entitäten, das grosszellige B-Zell-Lymphom, das follikuläre Lymphom, der Hodgkin und das Mantelzell-Lymphom machen aber mehr als die Hälfte aller Lymphome aus. Im revidierten Ann Arbor staging system gelten die Suffixe «A» und «B» nur noch für den Hodgkin. «E» erscheint nur noch bei Stadien I und II. Eine Knochenmarksuntersuchung wird beim Hodgkin nicht mehr verlangt, beim DLBCL (Diffuse large B cell lymphoma) nur, falls das PET keinen Knochenmark-Befall zeigt. Der PET-Untersuchung, speziell dem Interim-PET, kommt eine entscheidende Bedeutung zu. PET-gesteuerte Therapien führen zu weniger Toxizität. Gezielt wirkende Medikamente mit eindrücklicher Wirksamkeit wurden neu zugelassen. Deren Kosten sind hoch. Eine strahlen- und chemotherapiefreie Behandlung maligner Lymphome wird in Zukunft möglich sein.

Sign in / Sign up

Export Citation Format

Share Document